BRTX · XBRL financial data

BioRestorative Therapies financial statements, every quarter

The same tables from 13 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (BRTX's year ends in late December)

In thousands of dollars	Q2 FY23Jun 30, 2023	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026
Revenue from contracts with customers	65	31	19*	35	89	234	43*	25	303	12	20*	23
Cost of goods and services sold	—	—	—	—	6	18	3*	3	9	11	2*	7
Gross profit	65	31	—	35	83	215	40*	22	295	1	18*	16
Research and development	968	875	681*	1,058	1,292	1,320	1,658*	1,714	2,226	2,595	2,627*	1,926
General and administrative	2,213	2,260	2,559*	3,086	1,259	1,182	1,072*	3,115	1,374	1,115	1,216*	1,475
Total operating expenses	3,181	3,135	3,240*	4,144	2,551	2,502	2,730*	4,830	3,600	3,710	3,843*	3,402
Operating income (loss)	(3,117)	(3,104)	(3,221)*	(4,109)	(2,469)	(2,287)	(2,690)*	(4,808)	(3,305)	(3,709)	(3,825)*	(3,386)
Other income (expense)	40	34	19*	149	1	1	0*	2	1	1	14*	6
Net income (loss)	(2,981)	(2,925)	1,173*	(2,223)	(4,029)	(1,091)	(1,636)*	(5,340)	(2,656)	(3,038)	(3,208)*	(2,154)
Earnings per share, basic USD per share	(0.77)	(0.64)	—	(0.33)	(0.50)	(0.13)	(0.20)*	(0.64)	(0.30)	(0.33)	(0.33)*	(0.12)
Earnings per share, diluted USD per share	(0.77)	(0.64)	—	(0.33)	(0.50)	(0.13)	(0.20)*	(0.64)	(0.30)	(0.33)	(0.33)*	(0.12)
Weighted average shares, basic thousands of shares	3,886	4,571	4,684*	6,671	8,121	8,121	8,133*	8,357	8,740	9,116	9,742*	17,728
Weighted average shares, diluted thousands of shares	3,886	4,571	4,684*	6,671	8,121	8,121	8,133*	8,357	8,740	9,116	9,742*	17,728

Balance sheet

CSV

Fiscal quarters (BRTX's year ends in late December)

In thousands of dollars	Q2 FY23Jun 30, 2023	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026
Cash and cash equivalents	1,784	2,437	884	1,157	2,252	1,489	548	1,229	1,555	602	1,511	3,113
Marketable securities	9,832	9,802	10,182	15,261	12,428	11,598	10,185	7,884	5,826	3,887	1,442	479
Accounts receivable	25	39	19	35	27	165	188	25	15	13	16	13
Prepaid and other current assets	404	326	305	317	296	234	223	217	202	204	168	194
Total current assets	12,044	12,604	11,391	16,770	15,004	13,509	11,144	9,355	7,598	4,707	3,137	3,800
Property and equipment, net	314	306	356	365	346	378	363	370	340	309	359	329
Right-of-use asset	184	155	151	115	78	40	—	—	—	—	—	—
Total assets	13,300	13,801	12,612	17,951	16,119	14,573	12,280	10,327	8,517	5,643	4,080	4,640
Accounts payable	276	227	189	231	216	401	483	600	610	860	1,341	667
Accrued liabilities	386	549	712	338	448	682	744	—	—	—	—	—
Total current liabilities	813	933	2,607	3,448	5,320	4,582	3,748	4,182	3,671	3,436	3,723	1,615
Lease liability, non-current	84	42	—	—	—	—	—	—	—	—	—	—
Total liabilities	896	975	2,607	3,448	5,320	4,582	3,748	4,182	3,671	—	—	—
Accumulated deficit	(161,306)	(164,231)	(146,699)	(148,923)	(152,951)	(154,043)	(155,679)	(161,019)	(163,675)	(166,713)	(169,921)	(172,075)
Total stockholders' equity	12,404	12,826	10,004	14,503	10,799	9,992	8,531	6,145	4,845	2,207	357	3,026
Total liabilities and equity	13,300	13,801	12,612	17,951	16,119	14,573	12,280	10,327	8,517	5,643	4,080	4,640
Common shares outstanding (cover page) thousands of shares	4,668	4,707	6,770	6,770	6,920	6,920	7,505	7,505	7,978	8,876	25,478	25,478

Cash flows

CSV

Fiscal quarters (BRTX's year ends in late December)

In thousands of dollars	Q2 FY23Jun 30, 2023	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026
Net income (loss)	(2,981)	(2,925)	1,173*	(2,223)	(4,029)	(1,091)	(1,636)*	(5,340)	(2,656)	(3,038)	(3,208)*	(2,154)
Stock-based compensation	1,486*	1,494*	1,464*	2,028	324*	284*	176*	2,009	469*	400*	448*	290
Depreciation and amortization	42*	—	—	—	—	—	—	—	—	—	—	—
Net cash from operating activities	(1,130)*	(1,178)*	(1,773)*	(2,318)	(1,865)*	(1,700)*	(2,348)*	(2,779)	(2,694)*	(2,901)*	(2,415)*	(3,808)
Purchases of property and equipment	29*	12*	70*	—	—	58*	12*	36	0*	0*	80*	—
Net cash from investing activities	666*	(23)*	101*	(4,928)	2,973*	937*	1,533*	2,367	2,132*	1,998*	2,401*	968
Proceeds from issuing common stock	—	1,442*	0*	—	—	—	—	1,084	927*	0*	1,085*	—
Proceeds from issuing equity	—	—	—	7,528	0*	—	—	—	—	—	—	—
Share repurchases	—	—	—	—	—	—	—	—	—	—	year only	0
Net cash from financing activities	—	1,854*	83*	7,518	(13)*	0*	(126)*	1,093	888*	(49)*	923*	4,441
Net change in cash	(53)*	653*	(1,590)*	273	1,095*	(763)*	(942)*	681	326*	(953)*	909*	1,601

Compare with peers

SIC 8090 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 8090 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
BioRestorative Therapies	3,113	23	(3,808)	25.5M	0.9 quarters	Q1 FY26 10-QMar 31, 2026
IMAC Holdings	45	21	(1,434)*	3.8M	0.0 quarters	Q3 FY25 10-QSep 30, 2025
Marpai	138	4,166	(4,099)*	26.8M	0.0 quarters	Q2 FY26 10-QJun 30, 2026
Mangoceuticals	229	69	(261)*	21.6M	0.9 quarters	Q2 FY26 10-QJun 30, 2026
Elite Health Systems	1,302	1,310	(1,353)*	28.5M	1.0 quarters	Q2 FY26 10-QJun 30, 2026
Cryo Cell International	1,426	7,824	1,142*	8.1M	—	Q3 FY26 10-QAug 31, 2026
Pacific Health Care Organization	2,653	1,513	507*	12.8M	—	Q3 FY26 10-QSep 30, 2026
BioCorRx	21	88	(440)*	29.8M	0.0 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.